Exhibit 10.13


    
      

    

    

      CONFIDENTIAL
        TREATMENT REQUESTED


      Gencarelli
        Group

      209
        Pennsylvania Avenue, SE

      Washington,
        D.C. 20003

      (202)543-6972

       

      December
        29, 2006

      


      Eugene
        Seymour, MD

      Chief
        Executive Officer

      Nanoviricides,
        Inc.

      135
        Wood
        Street, Suite 205

      West
        Haven, Connecticut 06516

      


      Re:
        Nanoviricides, Inc. Collaboration with U.S. Military and Civilian Research
        Agencies and International Health Agencies, 2006-2007

      


      Dear
        Dr.
        Seymour:

      


      I
        am
        writing to establish a record of work done in recent months to put in place
        formal collaborative arrangements between Nanoviricides, Inc. and U.S. Federal
        research agencies.

      


      U.S.
        Military—wwwwww xxxx xxxx xxxxxxxxx xxx xxxxxxxx xxxxxxx

      


      In
        June
        of 2006 Nanoviricides, Inc. began discussions with Colonel xxxxx xxxxx, Chief,
        xxxxxxxxxx xxxxxxxxx xxxxx, about possible common interests and goals in
        the
        area of anti-viral treatment research. This meeting led to technical discussions
        in September wherein Colonel xxxxxx xxxxxx xxxxxx, Ph.D., Director, xxxxxxxx
        xx
        xxxxx xxxxxxxxx xxxxx, initiated dialogue with Nanoviricides, Inc. about
        a
        Cooperative Research and Development Agreement (CRADA) designed to test the
        effectiveness of the Nanoviricides, Inc. anti-viral approach against three
        diseases of interest at xxxxx, namely Dengue Fever, West Nile Virus and Japanese
        Equine Encephalitis (JEE). 

      


      As
        of
        December 22, 2006, Nanoviricides, Inc. officials have submitted required
        information for formalization of the CRADA and await sign-off by xxxxx officials
        so that work can begin within 45-60 days. This work will initially test a
        combination of the Nanoviricides, Inc. polymer and targeting antibody fragments
        derived from the specified diseases against the three diseases themselves
        in an
        in vitro setting. When these in vitro tests show adequate effectiveness,
        it is
        xxxxx’s intention to continue testing with this combination in primates where
        Dengue fever will be the primary focus. Nanoviricides, Inc. can reasonably
        expects both of these experimental tracks to move forward during the 2007
        calendar year.

      


      
        
          
            
            

          

          
            
            

            
              

            

          

          
            
            

          

        

      

       

      CONFIDENTIAL
        TREATMENT REQUESTED


       

      Page
        2-Nanoviricides, Inc. Collaboration with U.S. Military and Civilian Research
        Agencies, 2006-2007

      


      United
        States National xxxxxxxxx xxx xxxxxxxxx xxx xxxxxxxxxx xxxxxxx
        xxxxxxxxxx

      


      Nanoviricides,
        Inc. began discussions in September of this year with Dr. xxxxxx xxxxxxxxxxx
        Chief, Influenza, SARS, and Other Viral Respiratory Diseases Section Division
        of Microbiology
        and Infectious Diseases xxxxxxxxxxxxx, and program manager xxxxxxx xxxxxxxxxx
        about participating in xxxxx’s Small business testing and evaluation program
        which provides no-cost testing of novel immunotherapeutic treatment and vaccines
        against diseases considered priorities for the Institute. Nanoviricides,
        Inc.
        and xxxxx are now in the process of finalizing paperwork for bioassay (in
        vitro)
        testing to be done against HIV (AIDS), Influenzas, H5N1, SARS, and Herpes
        over
        the next few months. Assuming adequate effectiveness is shown in the in vitro
        testing, the goal will be to move on to animal studies on the same diseases.
        Actual experimentation will be done by xxxxx contractor xxxx xxxxx with all
        costs (other than production of Nanoviricides, Inc. materials) borne by xxxxx.
        xxxxx has indicated that if there are no unforeseen delays, both bioassay
        and
        animal studies could begin before the end of calendar year 2007.

      


      Also
        in
        2006, Nanoviricides, Inc. has spent time exploring possible collaboration
        opportunities with foreign research institutes under the auspices of the
        xxx
        xxxxxxxx xxxxxx xxxxxxxxxxxx and the xxxxx xxxxxx xxxxxxxxxxxx. The company
        has
        met on numerous occasions with Dr. xxxx xxxxxxxxx xx xxxx, well known for
        his
        efforts to bring novel pharmaceutical solutions to populations in underdeveloped
        countries where “orphan” or “neglected” disease take an inordinate toll on
        indigenous peoples. One of his most important contributions has been arrangement
        of collaborations with the pharmaceutical industry which have significantly
        reduced river blindness sickness in Africa. With Dr. xxxxxxxxx’s encouragement,
        Nanoviricides, Inc. has met with Dr. xxxxxx xxxxxx, Executive Director, Tropical
        Disease Research Institute of the xxx, in Washington, DC and later in Geneva,
        Switzerland to identify target diseases and research institutes in South
        and
        Central America which that may be potential collaborators. This work is expected
        to produce commercial and humanitarian opportunities relating to diseases
        common
        to this region of the world.

      


      I
        hope
        this summary adequately explains the state of play between Nanoviricides,
        Inc.
        and two key government collaborators. Gencarelli Group stands ready to answer
        detailed questions on these projects.

      


      
        	 	
                /s/
                  Dave Gencarelli

              
	 	
                Dave
                  Gencarelli, Gencarelli Group 

              
	 	
                202-256-6191